A novel Tn antigen epitope?recognizing antibody for MUC1 predicts clinical outcome in patients with primary lung adenocarcinoma

Mucin 1 (MUC1) expression is upregulated in multiple types of cancer, including lung cancer. However, the conventional anti?MUC1 antibody not useful for differentiation malignant tumors and benign lesions due to its limited specificity. Our previous study screened a novel epitope?defined against cancer?associated sugar chain structures that specifically recognizes MUC1 Tn antigen (MUC1?Tn ED Ab). In present study, potential utility as diagnostic marker therapeutic tool adenocarcinoma (ADC) was examined. Immunohistochemical analysis ADC tissue microarray performed using MUC1?Tn Ab (clone SN?102), results were compared with those another clone commercially available antibodies. The association between positive immunoreactivity SN?102 clinicopathologic factors analyzed. Furthermore, epithelial?mesenchymal transition markers radiological characteristics Moderate or high (MUC1?Tn?H) observed 138 (78.9%) 175 cases. MUC1?Tn?H associated male sex, cigarette smoking, tumor extension, pleural invasion, higher preoperative serum carcinoembryonic cytokeratin 19 fragment levels. Tumors had consolidation/tumor ratios according computed tomography greater uptakes 18F?fluorodeoxyglucose. A total 46 (26.9%) mesenchymal features, positivity group than epithelial intermediate groups (P<0.01 P<0.01, respectively). Patients exhibiting significantly shorter 5?year overall disease?free survival times (P=0.011 P<0.001, Additionally, identified an independent prognostic factor multivariate (P=0.024). specific cancer cells can improve capabilities. it may be target ADC.